Home Cart Sign in  
Chemical Structure| 633-65-8 Chemical Structure| 633-65-8

Structure of Berberine chloride
CAS No.: 633-65-8

Chemical Structure| 633-65-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Berberine HCl is an isoquinoline alkaloid isolated from the herb of Coptis chinensis Franch with anti-inflammatory and anti-diabetic effects.

Synonyms: Natural Yellow 18 chloride; Berberine (chloride); NSC 163088

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Berberine chloride

CAS No. :633-65-8
Formula : C20H18ClNO4
M.W : 371.81
SMILES Code : COC1=CC=C2C=C3[N+](CCC4=C3C=C(OCO5)C5=C4)=CC2=C1OC.[Cl-]
Synonyms :
Natural Yellow 18 chloride; Berberine (chloride); NSC 163088
MDL No. :MFCD00011939
InChI Key :VKJGBAJNNALVAV-UHFFFAOYSA-M
Pubchem ID :12456

Safety of Berberine chloride

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
L540 cells 3 μM 16 h To evaluate the inhibitory effect of berberine chloride on constitutively active JAK3. Results showed that 3 μM berberine chloride significantly reduced phospho-JAK3 levels in L540 cells. Br J Pharmacol. 2011 Sep;164(1):106-18
BaF3-JAK3V674A cells 3 μM 16 h To evaluate the inhibitory effect of berberine chloride on constitutively active JAK3. Results showed that 3 μM berberine chloride significantly reduced phospho-JAK3 levels in BaF3-JAK3V674A cells. Br J Pharmacol. 2011 Sep;164(1):106-18
Nb2 cells 3 μM To evaluate the inhibitory effect of berberine chloride on IL-2-induced JAK3 and STAT5 phosphorylation. Results showed that 3 μM berberine chloride almost completely inhibited IL-2-induced JAK3 and STAT5 phosphorylation. Br J Pharmacol. 2011 Sep;164(1):106-18
32D/IL-2Rβ/6xSTAT5 cells 3.78 μM 16 h To evaluate the inhibitory effect of berberine chloride on IL-2-induced STAT5 reporter activity. Results showed that berberine chloride inhibited IL-2-induced STAT5 reporter activity in a concentration-dependent manner with an IC50 value of 3.78 μM. Br J Pharmacol. 2011 Sep;164(1):106-18
Mouse primary chondrocytes (WT and AMPK α1 KO) 5 μM 18 h To compare the anti-catabolic effects of berberine in WT and AMPK α1 KO chondrocytes. Results showed that berberine inhibited IL-1β-induced NO release in both cell types, but the extent of inhibition was significantly lower in AMPK α1 KO cells (40%) compared to WT cells (74%). Osteoarthritis Cartilage. 2022 Jan;30(1):160-171
Human primary knee chondrocytes 5 and 25 μM 18 h To investigate how berberine inhibits inflammatory responses via AMPK activation. Results showed that berberine at 5 and 25 μM increased phosphorylation of AMPK α (Thr172) and significantly inhibited IL-1β-induced phosphorylation of NF-κB (Ser536) and release of NO, MMP3, and MMP13. Osteoarthritis Cartilage. 2022 Jan;30(1):160-171

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Beagle dogs Healthy beagle dogs Oral administration 150, 300, 600 mg/dog (single dose); 300 mg/kg (multiple dose) Single dose group: one-time administration; Multiple dose group: continuous administration for 7 days To evaluate the pharmacokinetic differences between BBR sustained-release pellets and commercial tablets. Results showed pellets significantly prolonged half-life (from 24 h to 36 h) and reduced inter-subject variability. Asian J Pharm Sci. 2019 Sep;14(5):559-568
Male albino Wistar rats Cisplatin-induced nephrotoxicity, hepatotoxicity, and hyperlipidemia model Oral 500 mg/kg/day BvRE (equivalent to 51.45 mg/kg/day berberine chloride) Once daily for 9 days To evaluate the protective effects of BvRE against cisplatin-induced nephrotoxicity, hepatotoxicity, and hyperlipidemia. The results demonstrated that BvRE significantly reversed the cisplatin-induced impairments in liver and kidney functions and dyslipidemia in both prophylactic and curative regimens, with more pronounced effects in the prophylactic regimen. Antioxidants (Basel). 2019 Jun 19;8(6):185

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02969070 Hypercholesterolemia ... More >> Endothelial Dysfunction Less << Phase 3 Unknown March 2017 Italy ... More >> University of Naples "Federico II" Recruiting Naples, Italy, 80131 Contact: Giuseppe Giugliano, MD, PhD    +390817462240    giuseppe.giugliano@unina.it    Sub-Investigator: Raffaele Izzo, MD          Sub-Investigator: Maurizio Galderisi, MD          Sub-Investigator: Giuseppe Giugliano, MD, PhD Less <<
NCT02861261 Type 2 Diabetes Phase 3 Active, not recruiting August 2018 China, Shanghai ... More >> Ruijin hospital,Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China Less <<
NCT03378934 Coronary Artery Disease ... More >> Percutaneous Coronary Intervention Less << Phase 4 Recruiting April 2020 China, Beijing ... More >> Peking Union Medical College Hospital Recruiting Beijing, Beijing, China, 100730 Contact: Zhenyu Liu, M.D.    +861069155068    pumch_lzy@163.com    Contact: Lihong Xu, B.N.    +861069155068    xulihong1990@163.com Less <<
NCT03251716 Metabolic Syndrome ... More >> Female Schizophrenia Less << Not Applicable Completed - China, Tianjin ... More >> Tianjin Anding Hospital Tianjin, Tianjin, China, 300222 Less <<
NCT02296021 Gastritis Pep... More >>tic Ulcer Dyspepsia Less << Phase 4 Completed - China, Shanxi ... More >> Xijing Hospital of Digestive Diseases Xi'an, Shanxi, China, 710032 Less <<
NCT03029390 Prediabetes I... More >>mpaired Fasting Glucose Impaired Glucose Tolerance Less << Phase 4 Active, not recruiting May 2018 Mexico ... More >> Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 Less <<
NCT02084004 Type 2 Diabetes Mellitus Phase 2 Phase 3 Withdrawn(The sponsor have not... More >> enough money to support this trial) Less << April 2018 China, Shaanxi ... More >> Second Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China, 710004 The 323rd Hospital of People's Liberation Army Xi'an, Shaanxi, China, 710054 First Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China, 710061 Shaanxi Provincial People's Hospital Xi'an, Shaanxi, China, 710068 Less <<
NCT02633930 Gastritis Pep... More >>tic Ulcer Dyspepsia Less << Phase 4 Completed - China, Shanxi ... More >> Xijing Hospital of Digestive Diseases Xi'an, Shanxi, China, 710032 Xijing Hospital of Digestive Disease Xi'an, Shanxi, China, 710032 Less <<
NCT02365480 Ulcerative Colitis Phase 1 Active, not recruiting - United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 China, Shaanxi Fourth Military Medical University Xi'an, Shaanxi, China, 710032 Less <<
NCT02226185 Colorectal Adenoma Phase 2 Phase 3 Active, not recruiting June 2019 China ... More >> Shanghai Institute of Digestive Disease Shanghai, China, 200001 Less <<
NCT03333265 Colorectal Adenomas Phase 2 Phase 3 Recruiting December 31, 2020 China, Shaanxi ... More >> Xijing Hospital of Digestive Disease Recruiting Xi'an, Shaanxi, China, 710032 Contact: xiaohua li, MD, PH.D    13474299901    lixiaohua1982@fmmu.edu.cn    Contact: ying zhang, MD, PH.D    13310980140 Less <<
NCT02082756 Prediabetes Phase 2 Phase 3 Withdrawn(The sponsor have not... More >> enough money to support this trial) Less << April 2018 China, Shaanxi ... More >> First Affiliated Hospital of Xi'an Jiaotong University Xi'an,, Shaanxi, China, 710061 Second Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China, 710004 The 323rd Hospital of People's Liberation Army Xi'an, Shaanxi, China, 710054 Shaanxi Provincial People's Hospital Xi'an, Shaanxi, China, 710068 Less <<
NCT03330184 Berberine Hydrochloride Phase 3 Completed - China, Shaanxi ... More >> First Affiliated Hospital of Xi'an Jiaotong University Xi'an,, Shaanxi, China, 710061 Second Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China, 710004 Shaanxi Provincial People's Hospital Xi'an, Shaanxi, China, 710068 Less <<
NCT03281096 Colorectal Adenomas Phase 2 Phase 3 Recruiting March 1, 2021 China, Shaanxi ... More >> Xijing Hospital of Digestive Disease Recruiting Xi'an, Shaanxi, China, 710032 Contact: xiaohua li, MD, PH.D    13474299901    lixiaohua1982@fmmu.edu.cn    Contact: ying zhang, MD, PH.D    13310980140 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.45mL

2.69mL

1.34mL

26.90mL

5.38mL

2.69mL

References

 

Historical Records

Categories